- Home
- TRGP vs IQV Comparison
TRGP vs IQV Comparison
Compare TRGP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRGP | IQV |
|---|---|---|
| Founded | 2005 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8B | 36.4B |
| IPO Year | 2010 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TRGP | IQV |
|---|---|---|
| Price | $183.17 | $221.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | $211.79 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | ★ 7.42 | 7.30 |
| Revenue | ★ $17,378,100,000.00 | $15,904,000,000.00 |
| Revenue This Year | $12.72 | $6.14 |
| Revenue Next Year | $31.42 | $5.35 |
| P/E Ratio | ★ $24.70 | $30.43 |
| Revenue Growth | ★ 7.17 | 3.85 |
| 52 Week Low | $144.14 | $134.65 |
| 52 Week High | $218.51 | $234.30 |
Technical Indicators
Market Signals| Indicator | TRGP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 64.50 | 50.89 |
| Support Level | $176.53 | $217.86 |
| Resistance Level | $185.83 | $230.80 |
| Average True Range (ATR) | 4.39 | 5.33 |
| MACD | 0.62 | -1.09 |
| Stochastic Oscillator | 78.49 | 39.49 |
Price Performance
Historical ComparisonAbout TRGP Targa Resources Inc.
Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.